EAM
PHAT icon

Eagle Asset Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Eagle Asset Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$7.67M Buy
455,196
+93,733
+26% +$1.31M 0.04% 342
2024
Q2 		$3.91M Buy
361,463
+56,624
+19% +$583K 0.02% 414
2024
Q1 		$3.23M Buy
+304,839
New +$2.59M 0.02% 433

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Eagle Asset Management's PHAT Position: Q3 2024 in Review

Eagle Asset Management increased its Phathom Pharmaceuticals (PHAT) stake by 26% in Q3 2024, buying an estimated $1.31M and bringing the position to 455,196 shares worth $7.67M. The position accounts for 0.04% of the portfolio, ranked #342.

Eagle Asset Management first reported a position in PHAT in Q1 2024 and has held it in 3 quarters since. 133 funds tracked by Wall St. Rank hold PHAT as of Q3 2024.

  • Eagle Asset Management held 455,196 shares of Phathom Pharmaceuticals worth $7.67M as of Q3 2024.
  • Eagle Asset Management bought 93,733 Phathom Pharmaceuticals shares in Q3 2024, an estimated $1.31M.
  • Phathom Pharmaceuticals made up 0.04% of Eagle Asset Management's portfolio in Q3 2024, its #342 holding.
  • Eagle Asset Management first reported a position in Phathom Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • 133 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.